SENORES PHARMACEUTICALS LIMITED
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Strong cash conversion β FCF/PAT ratio of 87.25
Concerns1
- Low return on equity of 0.6%
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 5 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ39.00 Cr | β | βΉ4.00 Cr | β | β | 0.6% | 14.7% | 300.0% |
| Mar 2024 | βΉ34.00 Cr | β | βΉ1.00 Cr | β | β | 0.6% | 183.3% | 0.0% |
| Mar 2023 | βΉ12.00 Cr | β | βΉ1.00 Cr | β | β | 2.6% | -14.3% | 0.0% |
| Mar 2022 | βΉ14.00 Cr | β | βΉ1.00 Cr | β | β | 2.9% | 75.0% | 0.0% |
| Mar 2021 | βΉ8.00 Cr | β | βΉ1.00 Cr | β | β | 10.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 77 |
| Total Expenses | 81 |
| EBIT / Operating Profit | -5 |
| OPM % | -6% |
| Other Income | 36 |
| Finance Costs | 8 |
| Depreciation & Amortisation | 8 |
| Profit Before Tax | 15 |
| Tax % | - |
| Net Profit / PAT | 12 |
| EPS (βΉ) | 2.66 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| SENORES PHARMACEUTICALS LIMITEDthis co. | βΉ3.75 K Cr | βΉ39.00 Cr | 307.00 | 5.25 | 545.51 | 14.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |